



Nonafact

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision issued ² / amended on	Product Information affected ³	Summary
IB/0062	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	24/11/2016		SmPC, Annex II, Labelling and PL	
IAIN/0061	B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	30/08/2016	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IB/0059/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure</p>	20/05/2016	n/a		
II/0054	<p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p>	28/04/2016	n/a		
IAIN/0058/G	<p>This was an application for a group of variations.</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release</p>	22/03/2016		Annex II and PL	
IAIN/0060/G	<p>This was an application for a group of variations.</p> <p>B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes</p>	09/03/2016	n/a		

Medicinal product no longer authorised

	do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP				
IA/0057	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	03/02/2016	n/a		
T/0055	Transfer of Marketing Authorisation	15/12/2015	28/01/2016	SmPC, Labelling and PL	
IA/0056	B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	07/01/2016	n/a		
IAIN/0053	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMP location	08/12/2015	n/a		
IAIN/0052/G	This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.I.b.2.a - Change in test procedure for AS or starting	09/04/2015	n/a		

Medicinal product no longer authorised

	material/reagent/intermediate - Minor changes to an approved test procedure				
IB/0049	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	18/02/2015	n/a		
IA/0050	B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised	22/01/2015	n/a		
IAIN/0051	B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	19/01/2015	n/a		
IB/0048	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation	10/15/2014	n/a		
IAIN/0047	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	19/11/2014	n/a		
IAIN/0046	B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	10/06/2014	n/a		

Medicinal product no longer authorised

PSUSA/1617/ 201307	Periodic Safety Update EU Single assessment - HUMAN COAGULATION FACTOR IX	06/03/2014	n/a		PRAC Recommendation - maintenance
IAIN/0045/G	This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	27/02/2014	n/a		
IB/0043	B.I.z - Quality change - Active substance - Other variation	15/11/2013	n/a		
IB/0041	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	18/10/2013	n/a		
IB/0042	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	08/10/2013	n/a		
IA/0040	B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits	24/05/2013	n/a		
IB/0039	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of	23/05/2013	n/a		

Medicinal product no longer authorised

	the AS				
IAIN/0038/G	<p>This was an application for a group of variations.</p> <p>B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP</p> <p>B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP</p>	25/01/2013	n/a		
IB/0036/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>	01/10/2012	n/a		
IAIN/0037/G	<p>This was an application for a group of variations.</p> <p>B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP</p> <p>B.V.a.1.d - PMF - Inclusion of a new, updated or</p>	21/09/2012	n/a		

Medicinal product no longer authorised

	amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP				
IAIN/0035	B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	25/05/2012	n/a		
IA/0034	B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	04/05/2012	n/a		
IB/0033	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	21/03/2012	n/a		
II/0032	To replace a release test of the drug product. B.II.d.2.c - Change in test procedure for the finished product - Replacement of a biological/ immunological/immunochemical test method or a method using a biological reagent	15/03/2012	n/a		
II/0031	Changes in the test method for "Activated Factor IX" and finished product release specifications. B.II.d.2.c - Change in test procedure for the finished product - Replacement of a biological/	20/10/2011	20/10/2011		

Medicinal product no longer authorised

	immunological/immunochemical test method or a method using a biological reagent				
IB/0030/G	<p>This was an application for a group of variations.</p> <p>B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - First-time inclusion of a new PMF NOT affecting the properties of the FP</p> <p>B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP</p>	23/09/2011	n/a		
IB/0029	B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation	19/04/2011	n/a		
IA/0027	B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP	13/07/2010	n/a		
IB/0026	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	18/06/2010	n/a	SmPC, Annex II, Labelling and PL	
2PMF/0025	Inclusion of the updated or amended Plasma Master File (Sanquin EMEA/H/PMF/000007/04) in the marketing authorisation dossier	04/05/2009	n/a		

Medicinal product no longer authorised

IB/0024	IB_38_c_Change in test procedure of finished product - other changes	16/04/2009	n/a		
IA/0023	IA_25_b_01_Change to comply with Ph. - compliance with EU Ph. update - active substance	19/02/2009	n/a		
II/0022	Changes in the in-process controls of the drug product Change(s) to the test method(s) and/or specifications for the finished product	25/09/2008	02/10/2008		
MF/0021	2PMF (2nd step of PMF certification procedure)	01/07/2008	n/a		
IB/0020	Change in the reference standard IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient	15/01/2008	n/a		
II/0017	Update of Summary of Product Characteristics and Package Leaflet	24/05/2007	30/10/2007	SmPC and PL	Update of Section 4.4 and 4.8 of the SPC to bring them in line with the Note for Guidance on the Warning on Transmissible Agents for Plasma-derived medicinal products. The Package Leaflet has been updated accordingly.
II/0016	Quality changes	19/07/2007	24/07/2007		
MF/0018	2PMF (2nd step of PMF certification procedure)	16/05/2007	n/a		
IA/0019	IA_25_b_01_Change to comply with Ph. - compliance with EU Ph. update - active substance	07/05/2007	n/a		
R/0012	Renewal of the marketing authorisation.	01/06/2006	25/07/2006	SmPC, Annex II, Labelling and PL	The renewal was granted with unlimited validity, with a PSUR cycle of 3 years.

Medicinal product no longer authorised

MF/0013	2PMF (2nd step of PMF certification procedure)	20/07/2006	n/a		
II/0011	Quality changes	23/03/2006	28/03/2006		
MF/0009	2PMF (2nd step of PMF certification procedure)	25/01/2006	n/a		
II/0008	Quality changes	14/12/2005	21/12/2005		
IA/0007	IA_28_Change in any part of primary packaging material not in contact with finished product	12/04/2005	n/a		The MAH applied to change the colour of the sealing cap from red (article code 06-066) to turquoise (article code 06-070). The sealing cap does not contact the finished product.
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	16/12/2004	n/a	PL	The MAH applied to update the list of local representatives to include the accession countries.
II/0005	Update of or change(s) to the pharmaceutical documentation	21/01/2004	26/01/2004		
I/0003	24_Change in test procedure of active substance 25_Change in test procedures of the medicinal product 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance	24/07/2003	05/08/2003		
I/0002	25_Change in test procedures of the medicinal product	08/05/2003	14/05/2003		
I/0001	03_Change in the name and/or address of the marketing authorisation holder	04/04/2003	12/05/2003	SmPC, Labelling and PL	

Medicinal product no longer authorised